EMA panel endorses AI for MASH clinical trials
PathAI's artificial intelligence tool for diagnosing MASH has become the first to be recommended under the EMA's Qualification Opinion framework.
AZ builds in China, as J&J ramps up its US investments
AstraZeneca will open its sixth R&D centre in China, while J&J announces four new manufacturing facilities in the US in a major reshoring drive.
Fabhalta is first FDA-approved therapy for rare disease C3G
Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.
J&J adds to IL-23 options in Crohn's after FDA approval
J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.
Alnylam joins three-way contest in ATTR cardiomyopathy
Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
Oncology
Patients
R&D
Partner Content
Innovation in Psychosis Therapeutics Summit
Join leaders at the Innovation in Psychosis Therapeutics Summit to revolutionize psychosis treatment
4th ALS Drug Development Summit
Join 200+ experts at the 4th ALS Summit to advance biomarkers, targets, and trials for ALS & FTD
London Biotechnology Show
London Biotechnology Show Levels Up with Industry Pioneers in Exhibitor Lineup, Hosted Buyer Programme
2nd GLP-1-Based Therapeutics Summit
If you thought that 2024 was the year for GLP-1 Agonists, then hold on for 2025!
5th Inner Ear Disorders Therapeutics Summit
Coined by industry as the only meeting of its kind, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical, translational, and clin